会议专题

Effects of Unidentified Renal Insufficiency on the Safety and Efficacy of Chemotherapy for Metastatic Colorectal Cancer Patients

  ”Purpose” This study aims to determine the effects of unidentified renal insufficiency (URI) on the safety and efficacy of chemotherapy for metastatic colorectal cancer (mCRC) patients.”Methods” Medical records of mCRC patients with normal serum creatinine and who were treated with XELOX as the first-line therapy were retrospectively reviewed.Creatinine clearance (CrCL) was estimated using the Cockcroft-Gault formula.URI characterized by a CrCL of less than 60 ml/min.Logistic regression was used to assess the effects of URI on toxicities and response rates.Kaplan-Meier curve was used to evaluate the effect of URI on survival.”Results” A total of 143 patients were enrolled,of whom 34.9% had URI.Compared with the control group,the URI group had longer toxicity durations and developed significantly more grade 1 to 2 toxicities after adjusting for age,gender,and body mass index.The toxicities include myelosuppression (76.0% vs.60.5%,OR=1.86,95%CI=0.39~6.53,P<0.001),diarrhea (34.0% vs.29.0%,OR=3.76,95% CI=0.95~11.53,P< 0.001) ,stomatitis(10.0% vs.6.45%, OR=2.81,95% CI=1.10~4.28, P<0.001), and hand-foot syndrome (18.0% vs.6.45%,OR=2.56,95% CI=0.86~5.41, P=0.006).The response rate and time to progression were significantly lower in the URI group than that in the control group (4.5 months vs.5.5 months,Log-rank 7.259, P=0.007),whereas the overall survival rates of the two groups were similar.”Conclusions” URI can increase the toxicity and decrease the survival of XELOX-treated mCRC patients.Renal function screening via CrCL estimation is required for all mCRC patients before initial chemotherapy.

renal insufficiency colorectal cancer X ELOX safety efficacy

Jian Chen Xiao-ting Wang Lin-run Wang

Department of Pharmacy,The First Affiliated Hospital,College of Medicine,Zhejiang University,Hangzho Department of Medical Oncology,The First Affiliated Hospital,College of Medicine,Zhejiang University

国内会议

2013抗肿瘤药物研究新进展与肿瘤个性化药物治疗论坛

杭州

英文

234-240

2013-10-01(万方平台首次上网日期,不代表论文的发表时间)